American Vanguard Corporation — FY2011 Form 10-K
Reporting period: Year ended December 31, 2011; the filing also reports fourth-quarter results. Amounts below are in $thousands unless stated otherwise. The company is a specialty chemical manufacturer and marketer serving agricultural and commercial markets, with one reportable segment.
Financial performance and liquidity
| Metric | 2011 | 2010 | Change |
|---|---|---|---|
| Net sales | $304,429 | $226,859 | +34% |
| Gross profit / margin | $123,068 / 40% | $86,321 / 38% | Margin +2 percentage points |
| Operating income | $39,226 | $19,191 | More than doubled |
| Net income | $22,068 | $10,984 | +101% |
| Diluted earnings per share | $0.79 | $0.40 | +$0.39 |
| Cash from operating activities | $39,266 | $33,190 | +$6,076 |
| Cash and working capital at year-end | $35,085 / $99,440 | $1,158 / $69,046 | Cash and working capital increased |
| Total indebtedness | $66,377 | $62,139 | +$4,238 |
Operating expenses rose to $83,842 from $67,130, while declining as a share of sales to 28% from 30%. Income tax expense was $13,155, with a 37.35% effective rate versus 32.1%. Capital expenditures were $6,261; net cash used in investing activities was $6,577. The company paid $2,205 in dividends, or $0.08 per share.
Year-end receivables rose to $68,611 from $33,833, chiefly reflecting strong late-year sales; inventories decreased to $71,068 from $74,054. Management said operating cash and cash on hand should cover working-capital and capital-expenditure needs for at least 12 months. The $137,000 senior secured credit facility matures January 10, 2016; the company reported covenant compliance and up to $75,000 of additional borrowing capacity. Substantially all assets are pledged as collateral.
Fourth-quarter 2011 sales were $84,680, gross profit $33,912, net income $6,431, and diluted EPS $0.23.
Material changes versus 2010
- Crop sales increased 35% to $275,417; non-crop sales rose 24% to $29,012. Insecticide sales rose 63% to $137,460, with strong granular soil insecticide demand.
- Management attributed growth to favorable crop economics and acreage, pest and weed-resistance pressures, and products acquired in late 2010. Aztec, Mocap, and Nemacur together accounted for about half of the year-over-year crop sales increase. Mocap supply was short of demand.
- Gross margin improved with higher production volumes, manufacturing efficiencies, Folex production at the Axis facility, and a more favorable product mix. Research, product development, and regulatory expense increased by $5,406; total operating expenses increased by $16,712.
- Operating cash flow improved, but receivables grew substantially. Cash rose to $35,085 from $1,158; total debt increased moderately, while the working-capital revolver ended at zero.
Outlook, risks, contingencies, and unusual items
- Outlook: The filing provides no specific 2012 revenue or earnings guidance. Management warned that raw-material prices had been rising and expected further inflationary pressure through 2012 and 2013.
- Regulation and product supply: Many products require continuing registrations and re-registrations. The company identifies regulatory restrictions, sole-source suppliers, supply interruptions, raw-material costs, generic competition, GMO seeds, weather, and seasonal demand as significant risks.
- Customer concentration: Three distributors represented 55% of 2011 sales (26%, 18%, and 11%). The company also disclosed significant customer concentrations in year-end receivables.
- PCNB: A 2010 EPA stop-sale order was vacated by a court in August 2011; EPA approved registrations for major commercial uses in November. The company resumed limited late-season turf sales but had missed most of the season and remained without certain Canadian registrations. No PCNB loss contingency was recorded.
- Legal and environmental matters: The company disclosed numerous DBCP-related injury lawsuits, including newly filed cases; it stated losses were not probable or reasonably estimable and recorded no contingency for those cases. At its Commerce, California site, investigation and risk assessment continued; potential remediation costs could not be estimated, so no contingency was recorded. A Brazilian regulatory citation carried a $150 accrual for an estimated probable loss of $150–$200.
- Unusual financial items: Results included a $546 debt-extinguishment expense. A $2,857 reduction in acquisition-related earnout liabilities benefited cost of sales by $495 and operating expenses by $2,362. Final purchase-accounting entries added $6,802 to intangible assets and related liabilities without a cash impact.
The auditor issued an unqualified opinion on the financial statements and internal controls; management reported effective disclosure controls and internal control over financial reporting as of year-end.
Most important facts for investors to verify
- Whether the strong sales and margin gains persist after the benefit of acquired product lines, favorable crop conditions, and the reported earnout remeasurement.
- Whether receivables are collected on schedule and customer program accruals are adequate, given the year-end receivables increase and distributor concentration.
- Whether Mocap and other sole-source products can be supplied reliably, and whether rising raw-material costs affect margins.
- How PCNB sales and Canadian registration develop, and whether regulatory actions materially affect other products.
- Developments in DBCP litigation and Commerce-site environmental assessment; the filing does not provide estimable potential exposure for these matters.
- Debt repayment requirements, covenant headroom, variable-rate exposure, and the company’s ability to maintain liquidity through seasonal working-capital swings.